There are 2949 resources available
368MO - Fatty acid synthase inhibitor TVB-2640 with bevacizumab in recurrent glioblastoma
Presenter: William Kelly
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
369MO - Final results of depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO)
Presenter: Marta Padovan
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
370MO - FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma
Presenter: Jean-Sebastien Frenel
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
371MO - Usefulness of circulating tumour DNA detection from cerebrospinal fluid in recurrent high-grade glioma
Presenter: Maxime Fontanilles
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
372MO - Melanoma leptomeningeal metastases: A European multicenter cohort
Presenter: Emilie Le Rhun
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
373MO - Delivery and activity of SN-38 by sacituzumab govitecan in CNS tumours
Presenter: Andrew Brenner
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
LBA47 - Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
Presenter: Alexander Stratigos
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
530MO - Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
Presenter: Emiliano Calvo
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
531MO - VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy (IT) phase I clinical trials
Presenter: Alberto Hernando-Calvo
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
532MO - A phase Ib study of TQB2450 in combination with anlotinib in patients with advanced solid tumour
Presenter: Ying Cheng
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast